Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 3/20 | 0.52 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 2/20 | 0.52 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.52 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.52 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.52 |
| ▸ | KDM4A | O75164 | 12/20 | 0.69 |
| ▸ | KDM4C | Q9H3R0 | 12/20 | 0.69 |
| ▸ | KDM5A | P29375 | 1/20 | 0.66 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.66 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.66 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.52 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6647561 | 0.98 | KDM4A (0.66) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL6029256 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL5530872 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL219327 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL1176587 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL5219324 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL13286331 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL3402761 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL8213501 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 | |
| SCHEMBL28020165 | 0.98 | KDM4A (0.68) | KDM4AKDM4CKDM5AKDM7APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260315-A | Modification method of cellulose, betaine amphoteric cellulose and preparation method and application thereof | 深圳华源再生医学有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2025-01-30 | — | — | US | disclosed |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-10-29 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-01 | — | — | US | disclosed |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-08 | — | — | US | disclosed |
| CN-115260315-A | Modification method of cellulose, betaine amphoteric cellulose and preparation method and application thereof | 深圳华源再生医学有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-07-08 | — | — | US | disclosed |
| EP-2569276-B1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2021-02-24 | — | — | EP | disclosed |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-09-10 | — | — | US | disclosed |
| WO-2012000104-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011141703-A1 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B | PROTIVA BIOTHERAPEUTICS INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141705-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-11-17 | — | — | WO | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-5599781-A | Automatic dishwashing detergent having bleach system comprising monopersulfate, cationic bleach activator and perborate or percarbonate | PROCTER & GAMBLE COMPANY, THE | 1997-02-04 | — | — | US | disclosed |
| EP-0742280-A2 | Automatic dishwashing compositions comprising multiquarternary bleach activators | THE PROCTER & GAMBLE COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5520835-A | Automatic dishwashing compositions comprising multiquaternary bleach activators | THE PROCTER & GAMBLE COMPANY (US) | 1996-05-28 | — | — | US | disclosed |
| US-5011838-A | Antiallergens, antihistamines | DOMPE FARMACEUTICI S.P.A. (IT) | 1991-04-30 | — | — | US | disclosed |
| EP-0397615-A2 | Pharmacologically active 2-substituted 3-(2-ethoxyethyl) imidazo [4,5-b] pyridines and pharmaceutical compositions containing them | DOMPE' FARMACEUTICI S.p.A. (IT) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | PPARG 3682/4885HDAC11 1764/4885ESR1 4360/4885 |
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | PPARG 3682/4885HDAC11 1764/4885ESR1 4360/4885 |
| US-20210207140-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | PPARG 3682/4885HDAC11 1764/4885ESR1 4360/4885 |
| US-20200282060-A1 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF | PLIN3, CETP, LDLR | PPARG 2474/4885HDAC11 1237/4885ESR1 4630/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | PPARG 2297/4885HDAC11 127/4885ESR1 4751/4885 |
| US-20240035030-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | PPARG 3682/4885HDAC11 1764/4885ESR1 4360/4885 |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | PPARG 3682/4885HDAC11 1764/4885ESR1 4360/4885 |
| US-11718852-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | PPARG 3682/4885HDAC11 1764/4885ESR1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.